BioLine RX Ltd BLRX.OQ, BLRX.O is expected to show a rise in quarterly revenue when it reports results on March 18 (estimated) for the period ending December 31 2024
The Modiin Israel-based company is expected to report a 60.8% increase in revenue to $7.718 million from $4.8 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for BioLine RX Ltd is for a loss of 93 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for BioLine RX Ltd is $80.00, above its last closing price of $3.05.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -1.96 | -2.00 | 0.00 | Beat | 100 |
Jun. 30 2024 | -5.60 | -5.60 | 0.00 | Beat | 100 |
Mar. 31 2024 | -11.60 | -11.60 | -0.40 | Beat | 96.6 |
Dec. 31 2023 | -8.80 | -6.60 | -6.00 | Beat | 9.1 |
Sep. 30 2023 | -10.40 | -12.00 | Missed | -15.4 | |
Jun. 30 2023 | -4.40 | -5.20 | -12.00 | Missed | -130.8 |
Mar. 31 2023 | -7.14 | -6.80 | -6.00 | Beat | 11.8 |
Dec. 31 2022 | -3.60 | -5.00 | -6.00 | Missed | -20 |
This summary was machine generated March 14 at 11:50 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。